Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1698
    +0.0005 (+0.04%)
     
  • GBP/USD

    1.2621
    -0.0001 (-0.01%)
     
  • Bitcoin GBP

    56,004.41
    +940.45 (+1.71%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,404.98
    +236.91 (+0.59%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Medtronic Unveils MedTech Innovation Accelerator in China

Medtronic plc MDT recently launched the MedTech Innovation Accelerator at Pujiang International Science and Technology City in Minhang District, Shanghai. This is a first-of-its-kind approach by the med-tech major to expand in the field of early- stage med-tech innovation in China.

Over the past 30 years, the emerging economy of China has been one of the key focus areas for Medtronic. The company has expanded its base in the country through directsales, marketing, clinical training, R&D and product manufacturing.  With the latest move, the company is now set to expand into early stage MedTech innovation via venture investments, incubation and acceleration.

More on the MedTech Innovation Accelerator

The MedTech Innovation Accelerator is a collaborative flagship platform which is slated to provide services to global med-tech start-ups and cater to unmet clinical needs within China. Through the accelerator, Medtronic has primarily made the commitment to invest in China’s preliminary list of med-tech portfolio companies.

Numerous med-tech start-ups, within as well as outside China, have enrolled with the Innovation Accelerator as the preliminary roster of portfolio companies.

ADVERTISEMENT

These early-stage companies will be provided lab equipment at the Medtronic Technology Center. These companies will be guided by the Medtronic China R&D personnel in various stages of product development like prototype design, testing and quality control.

Support from Medtronic also comes in the form of guidance on clinical research, product registration, clinical training and manufacturing, among others. Equity investments by Medtronic China Ventures offer incentive for newer med-tech start-ups to join the platform.

The platform plans to focus on early stage innovation in AI, surgical robotics and neuromodulation in the days ahead.

Market Potential

China’s medical device industry has huge potential. It valued $18.8 billion in 2016 and is projected to reach a worth of $24 billion by 2019. The inauguration of the MedTech Innovation Accelerator is expected to upgrade China’s med-tech industry and strengthen Medtronic’s industrial foothold in the country. In this regard, in the last reported quarter, the company saw an impressive growth rate of 13% in China.

Recent International Developments

A key development by Medtronic in the international front has been the recent clearance and launch of Japan’s first bone grafting product for spine and orthopedic procedures.

In December 2018, the company announced a deal to acquire Israeli nutrition-related data services company, Nutrino Health Ltd. This acquisition is expected to strengthen Medtronic’s diabetes management segment.

Around the same time, Medtronic closed the acquisition of Israel-based Mazor Robotics. The buyout was made to integrate robotics-assisted spine surgery into Medtronic’s portfolio.

Price Performance

Over the past year, Medtronic has outperformed the industry it belongs to. The stock has rallied 16%, higher than the industry’s rise of 9.8%.

Zacks Rank and Key Picks

Currently, Medtronic carries a Zacks Rank #3 (Hold).

A few better-ranked stocks in the broader medical space are Stryker Corporation SYK, Penumbra, Inc. PEN and Varian Medical Systems, Inc VAR. Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Stryker’s long-term earnings growth rate is projected at 10%

Penumbra’s long-term earnings growth rate is estimated at 20.9%.

Varian’s long-term earnings growth rate is projected at 8%.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Penumbra, Inc. (PEN) : Free Stock Analysis Report
 
Varian Medical Systems, Inc. (VAR) : Free Stock Analysis Report
 
Medtronic PLC (MDT) : Free Stock Analysis Report
 
Stryker Corporation (SYK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.